Moulis G, Comont T, Adoue D
Service de Médecine Interne, CHU de Toulouse, France; UMR 1027 INSERM, Université de Toulouse, France; CIC 1436, CHU de Toulouse, France.
Service de Médecine Interne, Institut Universitaire du Cancer de Toulouse- Oncopôle, France.
Rev Med Interne. 2021 Jan;42(1):11-15. doi: 10.1016/j.revmed.2020.05.018. Epub 2020 Aug 11.
New insights into immune thrombocytopenia (ITP) epidemiology in adult patients highlight three main outcomes of morbidity and mortality: bleeding, infection and thrombosis. This review depicts current evidence about incidence and risk factors of bleeding, infection and thrombosis as well as predictors of chronicity, and shows how this assessment impacts the choice of ITP second-line treatment at the individual-level basis.
对成年免疫性血小板减少症(ITP)流行病学的新见解突出了发病率和死亡率的三个主要结果:出血、感染和血栓形成。本综述描述了关于出血、感染和血栓形成的发病率及风险因素以及慢性病预测因素的现有证据,并展示了这种评估如何在个体层面影响ITP二线治疗的选择。